Research programme: cancer immunotherapies - Arcus Biosciences

Drug Profile

Research programme: cancer immunotherapies - Arcus Biosciences

Alternative Names: LAG-3 antibody-Arcus Biosciences; STING targeting candidates-Arcus Biosciences; TIM-3 antibody-Arcus Biosciences; TLR4 targeting candidates-Arcus Biosciences

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arcus Biosciences
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Sep 2017 Arcus Biosciences and Taiho Pharmaceutical enter into option and license agreement to develop and commercialise immunotherapies for Cancer in Asia, including Japan and excluding China
  • 19 Sep 2017 Arcus Biosciences plans a clinical trials of its immunotherapies for Cancer in 2018
  • 28 Aug 2017 Preclinical trials in Cancer in USA (Parenteral) before August 2017 (Arcus Biosciences pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top